Aurobindo Pharma Limited

NSEI:AUROPHARMA Rapporto sulle azioni

Cap. di mercato: ₹717.5b

Aurobindo Pharma Gestione

Gestione criteri di controllo 3/4

Aurobindo Pharma Il CEO è Kambam Reddy, nominato in Jun2006, e ha un mandato di 18.42 anni. la retribuzione annua totale è ₹ 45.05M, composta da 50.9% di stipendio e 49.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.61% delle azioni della società, per un valore di ₹ 40.28B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 9.5 anni e 5.5 anni.

Informazioni chiave

Kambam Reddy

Amministratore delegato

₹45.0m

Compenso totale

Percentuale dello stipendio del CEO50.9%
Mandato del CEO18.4yrs
Proprietà del CEO5.6%
Durata media del management9.5yrs
Durata media del Consiglio di amministrazione5.5yrs

Aggiornamenti recenti sulla gestione

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Recent updates

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 07
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Jun 14
Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

May 21
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Feb 11
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price

Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Jan 09
Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly

Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

Nov 02
Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?

We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Jun 20
We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kambam Reddy rispetto agli utili di Aurobindo Pharma?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

₹36b

Jun 30 2024n/an/a

₹35b

Mar 31 2024₹45m₹23m

₹32b

Dec 31 2023n/an/a

₹28b

Sep 30 2023n/an/a

₹23b

Jun 30 2023n/an/a

₹20b

Mar 31 2023₹37m₹19m

₹19b

Dec 31 2022n/an/a

₹20b

Sep 30 2022n/an/a

₹21b

Jun 30 2022n/an/a

₹24b

Mar 31 2022₹27m₹14m

₹26b

Dec 31 2021n/an/a

₹29b

Sep 30 2021n/an/a

₹52b

Jun 30 2021n/an/a

₹53b

Mar 31 2021₹23m₹20m

₹53b

Dec 31 2020n/an/a

₹54b

Sep 30 2020n/an/a

₹31b

Jun 30 2020n/an/a

₹30b

Mar 31 2020₹15m₹13m

₹28b

Dec 31 2019n/an/a

₹26b

Sep 30 2019n/an/a

₹26b

Jun 30 2019n/an/a

₹25b

Mar 31 2019₹15m₹13m

₹24b

Dec 31 2018n/an/a

₹23b

Sep 30 2018n/an/a

₹22b

Jun 30 2018n/an/a

₹24b

Mar 31 2018₹15m₹13m

₹24b

Compensazione vs Mercato: La retribuzione totale di Kambam ($USD 533.60K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 776.13K ).

Compensazione vs guadagni: La retribuzione di Kambam è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Kambam Reddy (66 yo)

18.4yrs

Mandato

₹45,048,542

Compensazione

Mr. Kambam Nithyananda Reddy has been Vice Chairman of Aurobindo Pharma Limited since June 1, 2012 and serves as a Whole Time Director of Aurobindo Pharma Limited since December 26, 1986 and serves as Mana...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Kambam Reddy
Vice Chairman & MD18.4yrs₹45.05m5.61%
₹ 40.3b
Mettu Madan Reddy
Whole-Time Directorno data₹60.15mNessun dato
Makkapati Satakarni
President of Biologics8.8yrs₹300.00kNessun dato
Santhanam Subramanian
Chief Financial Officer10.3yrs₹21.06mNessun dato
S. Kumar
President of Technicalno dataNessun datoNessun dato
B. Reddy
Compliance Officer & Company Secretary8.4yrs₹4.76mNessun dato
G. Prasad
Senior Vice President of Global Finance & Operationsno dataNessun datoNessun dato
Sudhir Singhi
Head of Global Finance Operationsno dataNessun datoNessun dato
A. Rama Rao
Chief Quality Officer -Corporate QAno dataNessun dato0.025%
₹ 176.7m
V. Handa
President of Chemical Researchno dataNessun datoNessun dato
Gita Rao
President of RAD-IIno data₹9.14mNessun dato
Hemant Sharma
President-ARDno data₹10.09mNessun dato

9.5yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di AUROPHARMA è esperto e expertise (durata media dell'incarico 9.5 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Kambam Reddy
Vice Chairman & MD37.9yrs₹45.05m5.61%
₹ 40.3b
Mettu Madan Reddy
Whole-Time Director18.2yrs₹60.15mNessun dato
Makkapati Satakarni
President of Biologicsless than a year₹300.00kNessun dato
Penaka Venkata Reddy
Non-Executive Director37.9yrs₹600.00k3.07%
₹ 22.0b
Penaka Sarath Reddy
Non-Executive Director17.2yrs₹900.00kNessun dato
Santanu Mukherjee
Independent Director1.8yrs₹2.50mNessun dato
Deepali Pant Joshi
Independent Directorno data₹500.00kNessun dato
Savitha Mahajan
Additional Non-Executive Independent Director6.9yrs₹2.20mNessun dato
Venkat Chalasani
Independent Director of Apitoria Pharma Private Limited1.6yrsNessun datoNessun dato
Mangalam Kumar
Independent Non-Executive Chairmanless than a yearNessun datoNessun dato
Girish Vanvari
Non-Executive Independent Director4yrs₹2.60mNessun dato

5.5yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AUROPHARMA sono considerati esperti (durata media dell'incarico 5.5 anni).